AU2014356069B2 - Novel amino pyrimidine derivatives - Google Patents
Novel amino pyrimidine derivatives Download PDFInfo
- Publication number
- AU2014356069B2 AU2014356069B2 AU2014356069A AU2014356069A AU2014356069B2 AU 2014356069 B2 AU2014356069 B2 AU 2014356069B2 AU 2014356069 A AU2014356069 A AU 2014356069A AU 2014356069 A AU2014356069 A AU 2014356069A AU 2014356069 B2 AU2014356069 B2 AU 2014356069B2
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- fluoro
- halogen
- hydrogen
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195081 | 2013-11-29 | ||
| EP13195081.8 | 2013-11-29 | ||
| PCT/IB2014/066422 WO2015079417A1 (en) | 2013-11-29 | 2014-11-28 | Novel amino pyrimidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014356069A1 AU2014356069A1 (en) | 2016-05-05 |
| AU2014356069B2 true AU2014356069B2 (en) | 2017-06-15 |
Family
ID=49674216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014356069A Active AU2014356069B2 (en) | 2013-11-29 | 2014-11-28 | Novel amino pyrimidine derivatives |
Country Status (42)
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| KR102487608B1 (ko) | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
| CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| EP3180359A1 (en) | 2014-08-14 | 2017-06-21 | Novartis AG | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| KR102804360B1 (ko) | 2014-09-17 | 2025-05-12 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| US20180140602A1 (en) * | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| CA2981751A1 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
| WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
| AU2017225733A1 (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
| CN116769050A (zh) | 2016-07-20 | 2023-09-19 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
| MX2019003886A (es) | 2016-10-07 | 2019-08-05 | Novartis Ag | Receptores de antigenos quimericos para el tratamiento del cancer. |
| KR20190104528A (ko) | 2016-12-03 | 2019-09-10 | 주노 쎄러퓨티크스 인코퍼레이티드 | Car-t 세포들 투여를 결정하는 방법 |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| AU2018291032A1 (en) | 2017-06-29 | 2020-01-16 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| CN111511370A (zh) | 2017-11-01 | 2020-08-07 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体 |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| EP3703750B1 (en) | 2017-11-01 | 2024-12-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides |
| AR113796A1 (es) | 2017-11-06 | 2020-06-10 | Lilly Co Eli | Compuestos inhibidores de tirosina cinasa de bruton (btk) |
| WO2019109053A1 (en) | 2017-12-01 | 2019-06-06 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| CN108069911A (zh) * | 2017-12-14 | 2018-05-25 | 中国药科大学 | 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途 |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
| MX2021000925A (es) | 2018-07-25 | 2021-03-31 | Novartis Ag | Inhibidores de inflamasoma nlrp3. |
| EA202190557A1 (ru) | 2018-08-29 | 2021-07-13 | Асерта Фарма Б.В. | СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА |
| PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| JP2022513062A (ja) | 2018-11-16 | 2022-02-07 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法 |
| KR20210117260A (ko) | 2018-11-30 | 2021-09-28 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료방법 |
| CN113365660A (zh) | 2019-01-29 | 2021-09-07 | 朱诺治疗学股份有限公司 | 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| WO2020234780A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating asthma using a bruton's tyrosine kinase inhibitor |
| CA3137790A1 (en) * | 2019-05-23 | 2020-11-26 | Novartis Ag | Crystalline forms of a btk inhibitor |
| SI3972603T1 (sl) * | 2019-05-23 | 2025-02-28 | Novartis Ag | Postopki zdravljenja sjogrenovega sindroma z uporabo zaviralca brutonove tirozin kinaze |
| WO2020234782A1 (en) * | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor |
| US20230121818A1 (en) * | 2019-12-23 | 2023-04-20 | Biogen Ma Inc. | Btk inhibitors |
| AU2021251265A1 (en) | 2020-04-10 | 2022-11-03 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen |
| IL299091A (en) | 2020-08-14 | 2023-02-01 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and their medicinal uses |
| WO2022033569A1 (zh) * | 2020-08-14 | 2022-02-17 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物的晶型及其制备方法 |
| WO2022162513A1 (en) | 2021-01-26 | 2022-08-04 | Novartis Ag | Pharmaceutical composition |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| CA3229887A1 (en) | 2021-09-03 | 2023-03-09 | Novartis Ag | Lou064 for treating multiple sclerosis |
| EP4448114A1 (en) | 2021-12-14 | 2024-10-23 | Novartis AG | Methods of treatment using lou064 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| CA3263560A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics Inc | GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS |
| WO2024069507A1 (en) | 2022-09-30 | 2024-04-04 | Novartis Ag | Synthesis methods and intermediates for the production of remibrutinib |
| AR131320A1 (es) | 2022-12-13 | 2025-03-05 | Juno Therapeutics Inc | Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos |
| WO2025061148A1 (zh) * | 2023-09-22 | 2025-03-27 | 江苏恒瑞医药股份有限公司 | 杂芳基类化合物、其制备方法及其在医药上的应用 |
| CN117024354B (zh) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | 瑞米布替尼的制备方法 |
| US20250243170A1 (en) | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
| WO2025210469A2 (en) | 2024-04-02 | 2025-10-09 | Novartis Ag | Process of preparing remibrutinib substantially free of nitrosamine impurity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010100070A1 (en) * | 2009-03-02 | 2010-09-10 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| WO2013083666A1 (en) * | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| JP2004533209A (ja) | 2000-10-23 | 2004-11-04 | ブリストル−マイヤーズ スクイブ カンパニー | ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用 |
| KR100748386B1 (ko) | 2000-11-07 | 2007-08-10 | 노파르티스 아게 | 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체 |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| WO2004039956A2 (en) | 2002-10-29 | 2004-05-13 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7365096B2 (en) | 2002-12-09 | 2008-04-29 | Board Of Regents, The University Of Texas System | Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3) |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
| BRPI0410439A (pt) | 2003-05-19 | 2006-06-06 | Irm Llc | compostos e composições imunossupressoras |
| MXPA06007640A (es) | 2004-01-12 | 2007-04-17 | Cytopia Res Pty Ltd | Inhibidores de quinasa selectivos. |
| CN101223141A (zh) | 2005-03-10 | 2008-07-16 | Cgi药品股份有限公司 | 特定取代的酰胺，其制备方法和使用方法 |
| AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
| SG166093A1 (en) | 2006-09-22 | 2010-11-29 | Pharmacyclics Inc | Inhibitors of brutonæs tyrosine kinase |
| DK2134374T3 (en) | 2007-03-14 | 2014-02-24 | Bionsil S R L In Liquidazione | BTK-INHIBITORS FOR USE IN PROCESSING chemotherapeutic agent RESISTANT TUMORS Epithelial |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| MX2010013478A (es) | 2008-07-02 | 2010-12-20 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de cinasa. |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| US20100261776A1 (en) | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| EP2421854B1 (en) | 2009-04-24 | 2014-07-23 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| EP2539343B1 (en) * | 2010-02-26 | 2015-12-30 | Evotec International GmbH | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| JP6147727B2 (ja) | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体 |
| AU2012255759C1 (en) | 2011-05-17 | 2025-10-23 | Principia Biopharma, Inc. | Kinase inhibitors |
| SG10201604682VA (en) | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| AU2012275275A1 (en) | 2011-06-28 | 2014-01-23 | Pharmacyclics Llc | Methods and compositions for inhibition of bone resorption |
| CA2841111A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| EP2742138B1 (en) | 2011-08-09 | 2020-06-24 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells |
| US20140303191A1 (en) | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| CA2853498A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
| EP2824099A4 (en) | 2012-03-09 | 2015-11-11 | Carna Biosciences Inc | NOVEL TRIAZINE DERIVATIVE |
| JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2013173518A1 (en) | 2012-05-16 | 2013-11-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2014025976A1 (en) | 2012-08-10 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| JP6401169B2 (ja) | 2012-10-04 | 2018-10-03 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体 |
| US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2014
- 2014-11-13 US US14/540,140 patent/US9512084B2/en active Active
- 2014-11-27 UY UY0001035858A patent/UY35858A/es active IP Right Grant
- 2014-11-27 JO JOP/2014/0341A patent/JO3314B1/ar active
- 2014-11-27 AR ARP140104439A patent/AR098549A1/es active IP Right Grant
- 2014-11-28 SI SI201431570T patent/SI3299368T1/sl unknown
- 2014-11-28 DK DK17191467.4T patent/DK3299368T3/da active
- 2014-11-28 LT LTEP20158961.1T patent/LT3689865T/lt unknown
- 2014-11-28 NZ NZ718835A patent/NZ718835A/en unknown
- 2014-11-28 BR BR112016010397-1A patent/BR112016010397B1/pt active IP Right Grant
- 2014-11-28 MY MYPI2016701223A patent/MY179059A/en unknown
- 2014-11-28 MY MYPI2020002915A patent/MY191381A/en unknown
- 2014-11-28 CA CA2926908A patent/CA2926908C/en active Active
- 2014-11-28 DK DK20158961.1T patent/DK3689865T3/da active
- 2014-11-28 HU HUE14821285A patent/HUE037588T2/hu unknown
- 2014-11-28 KR KR1020227009823A patent/KR102421388B1/ko active Active
- 2014-11-28 TN TN2016000128A patent/TN2016000128A1/en unknown
- 2014-11-28 PL PL17191467T patent/PL3299368T3/pl unknown
- 2014-11-28 LT LTEP17191467.4T patent/LT3299368T/lt unknown
- 2014-11-28 HR HRP20171999TT patent/HRP20171999T1/hr unknown
- 2014-11-28 PT PT171914674T patent/PT3299368T/pt unknown
- 2014-11-28 HU HUE17191467A patent/HUE049794T2/hu unknown
- 2014-11-28 SI SI201430536T patent/SI3074386T1/en unknown
- 2014-11-28 RS RS20230437A patent/RS64275B1/sr unknown
- 2014-11-28 ES ES20158961T patent/ES2947770T3/es active Active
- 2014-11-28 KR KR1020167013830A patent/KR102380539B1/ko active Active
- 2014-11-28 FI FIEP20158961.1T patent/FI3689865T3/fi active
- 2014-11-28 TW TW103141506A patent/TWI652261B/zh active
- 2014-11-28 RS RS20171206A patent/RS56657B1/sr unknown
- 2014-11-28 MA MA39055A patent/MA39055B1/fr unknown
- 2014-11-28 PE PE2016000683A patent/PE20160869A1/es unknown
- 2014-11-28 DK DK14821285.5T patent/DK3074386T3/en active
- 2014-11-28 ES ES14821285.5T patent/ES2655527T3/es active Active
- 2014-11-28 ES ES17191467T patent/ES2791525T3/es active Active
- 2014-11-28 UA UAA201603623A patent/UA117256C2/uk unknown
- 2014-11-28 RS RS20200550A patent/RS60251B1/sr unknown
- 2014-11-28 EP EP25181626.0A patent/EP4606377A3/en active Pending
- 2014-11-28 SI SI201432031T patent/SI3689865T1/sl unknown
- 2014-11-28 CN CN201910288376.XA patent/CN110172056B/zh active Active
- 2014-11-28 PL PL14821285T patent/PL3074386T3/pl unknown
- 2014-11-28 EP EP17191467.4A patent/EP3299368B1/en active Active
- 2014-11-28 JP JP2016535053A patent/JP6342495B2/ja active Active
- 2014-11-28 EP EP23161775.4A patent/EP4219478B1/en active Active
- 2014-11-28 HR HRP20230585TT patent/HRP20230585T1/hr unknown
- 2014-11-28 AU AU2014356069A patent/AU2014356069B2/en active Active
- 2014-11-28 CU CU2016000078A patent/CU24384B1/es unknown
- 2014-11-28 NO NO14821285A patent/NO3074386T3/no unknown
- 2014-11-28 PL PL20158961.1T patent/PL3689865T3/pl unknown
- 2014-11-28 PT PT148212855T patent/PT3074386T/pt unknown
- 2014-11-28 ES ES23161775T patent/ES3040769T3/es active Active
- 2014-11-28 EP EP20158961.1A patent/EP3689865B1/en active Active
- 2014-11-28 EA EA201691125A patent/EA031218B1/ru not_active IP Right Cessation
- 2014-11-28 PT PT201589611T patent/PT3689865T/pt unknown
- 2014-11-28 LT LTEP14821285.5T patent/LT3074386T/lt unknown
- 2014-11-28 EP EP14821285.5A patent/EP3074386B1/en active Active
- 2014-11-28 HU HUE20158961A patent/HUE062248T2/hu unknown
- 2014-11-28 WO PCT/IB2014/066422 patent/WO2015079417A1/en not_active Ceased
- 2014-11-28 AP AP2016009158A patent/AP2016009158A0/en unknown
- 2014-11-28 CN CN201480058515.5A patent/CN105683181B/zh active Active
- 2014-11-28 MX MX2016006908A patent/MX367911B/es active IP Right Grant
-
2016
- 2016-04-05 ZA ZA2016/02275A patent/ZA201602275B/en unknown
- 2016-04-06 IL IL244943A patent/IL244943B/en active IP Right Grant
- 2016-04-21 US US15/135,296 patent/US20160235746A1/en not_active Abandoned
- 2016-04-28 PH PH12016500791A patent/PH12016500791A1/en unknown
- 2016-05-03 CL CL2016001055A patent/CL2016001055A1/es unknown
- 2016-05-27 SV SV2016005206A patent/SV2016005206A/es unknown
- 2016-05-27 CR CR20160244A patent/CR20160244A/es unknown
- 2016-06-20 EC ECIEPI201654826A patent/ECSP16054826A/es unknown
-
2017
- 2017-12-22 CY CY20171101345T patent/CY1119705T1/el unknown
-
2018
- 2018-05-08 US US15/974,190 patent/US10457647B2/en active Active
- 2018-05-16 JP JP2018094772A patent/JP6667573B2/ja active Active
-
2019
- 2019-09-16 US US16/571,405 patent/US11180460B2/en active Active
-
2020
- 2020-05-12 HR HRP20200775TT patent/HRP20200775T1/hr unknown
- 2020-05-25 CY CY20201100478T patent/CY1122924T1/el unknown
-
2021
- 2021-10-22 US US17/508,054 patent/US11673868B2/en active Active
-
2023
- 2023-05-01 US US18/309,948 patent/US20230312483A1/en active Pending
- 2023-06-27 CY CY20231100301T patent/CY1126056T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010100070A1 (en) * | 2009-03-02 | 2010-09-10 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| WO2013083666A1 (en) * | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014356069B2 (en) | Novel amino pyrimidine derivatives | |
| HK40089302B (en) | Method of preparing amino pyrimidine derivatives | |
| HK40024076B (en) | Novel amino pyrimidine derivatives | |
| HK40024076A (en) | Novel amino pyrimidine derivatives | |
| HK1252317B (en) | Novel amino pyrimidine derivatives | |
| HK1223368B (en) | Novel amino pyrimidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |